In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of cardiovascular disease. A total of 17,609 participants were enrolled by the investigators. In the investigator arm, participants received semaglutide injections as an adjunct to standard-of-care. The primary endpoint of this trial is the time to the first occurrence of a composite endpoint, which includes cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.
Support: This is an independent discussion produced by Radcliffe Cardiology.
Editor: Mirjam Boros, Jordan Rance
Videographers: Dan Brent, Mike Knight